Extract notice to the Minister

Ilumya (psoriasis en plaques)

Common name / Subject : tildrakizumab
Name of the manufacturer : Sun Pharma
Form : Sol. Inj. S.C. (stylo)
Dosage : 100 mg/ml (1 ml)

Indication : Psoriasis en plaques

INESSS' Recommendation
Inscription - Sous conditions

Minister's decisions
Inscription sur les listes des médicaments, Médicament d'exception (2026-03-04)

Evaluation published on February 18, 2026

INESSSid: 28245
Recevable on September 02, 2025

Download Advice to minister about Ilumya (psoriasis en plaques)

Extrait d'avis à la ministre sur Ilumya 328 KiO

Subscribe to our newsletter now

Subscription